{
    "clinical_study": {
        "@rank": "51907", 
        "arm_group": {
            "arm_group_label": "HBV Group", 
            "arm_group_type": "Experimental", 
            "description": "Subjects who will receive a challenge dose of Engerix\u2122-B Kinder."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the long-term persistence of immunity to hepatitis B\n      in adolescents aged 15-16 years who were vaccinated with Engerix\u2122-B Kinder in infancy. The\n      study will also assess the immune response to a challenge dose of Engerix\u2122-B Kinder in these\n      subjects."
        }, 
        "brief_title": "Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix\u2122-B Kinder", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B"
            ]
        }, 
        "detailed_description": {
            "textblock": "This MDD has been updated following the Protocol Amendment 1, dated 20 June 2013.\n\n      The Protocol was amended because GSK replaced its in-house Enzyme-Linked ImmunoSorbent Assay\n      (ELISA) that was used to measure anti-HBs (antibodies to Hepatitis B surface antigen)\n      antibody concentrations with ChemiLuminescence ImmunoAssay (CLIA).\n\n      Additionally, the threshold level of prednisone was modified to reflect the dosage normally\n      prescribed to adolescents."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject's parent(s)/guardians who, in the opinion of the investigator, can and will\n             comply, with the requirements of the protocol.\n\n          -  A male or female between, and including, 15 and 16 years of age at the time of the\n             vaccination.\n\n          -  Written informed consent obtained from the parent(s)/LAR(s) of the subject.\n\n          -  Written informed assent obtained from the subject in addition to the informed consent\n             signed by the parent(s)/LAR(s).\n\n          -  Healthy subjects as established by medical history and clinical examination before\n             entering into the study.\n\n          -  Documented evidence of previous vaccination with three consecutive doses of\n             Engerix\u2122-B Kinder in Germany: with the first two doses received by 9 months of age\n             and the third dose received by 18 months of age.\n\n          -  Female subjects of non-childbearing potential may be enrolled in the study.\n\n               -  Non-childbearing potential is defined as pre-menarche, current tubal ligation,\n                  hysterectomy, ovariectomy or post-menopause.\n\n          -  Female subjects of childbearing potential may be enrolled in the study, if the\n             subject:\n\n               -  has practiced adequate contraception for 30 days prior to vaccination, and\n\n               -  has a negative pregnancy test on the day of vaccination, and\n\n               -  has agreed to continue adequate contraception during the entire treatment period\n                  and for 2 months after completion of the vaccination.\n\n        Exclusion Criteria:\n\n          -  Child in care.\n\n          -  Use of any investigational or non-registered product other than the study vaccine\n             within 30 days preceding the dose of study vaccine, or planned use during the study\n             period.\n\n          -  Chronic administration  of immunosuppressants or other immune-modifying drugs within\n             six months prior to the vaccine dose. For corticosteroids, this will mean prednisone\n             \u2265 20 mg/day, or equivalent. Inhaled and topical steroids are allowed.\n\n          -  Previous hepatitis B vaccination since administration of the third dose of Engerix\u2122-B\n             Kinder.\n\n          -  History of hepatitis B disease.\n\n          -  Administration of a vaccine not foreseen by the study protocol within the period\n             starting 30 days before study vaccine dose, or planned administration during the\n             study period.\n\n          -  Concurrently participating in another clinical study, at any time during the study\n             period, in which the subject has been or will be exposed to an investigational or a\n             non-investigational vaccine/product.\n\n          -  History of any reaction or hypersensitivity likely to be exacerbated by any component\n             of the vaccine.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on\n             medical history and physical examination.\n\n          -  Acute disease and/or fever at the time of enrollment.\n\n               -  Fever is defined as temperature \u2265 37.5\u00b0C for oral, axillary or tympanic route,\n                  or \u2265 38.0\u00b0C on rectal route. The preferred route for recording temperature in\n                  this study will be axillary.\n\n               -  Subjects with a minor illness without fever may be enrolled at the discretion of\n                  the investigator.\n\n          -  Administration of immunoglobulins and/or any blood products within the 3 months\n             preceding the study vaccine dose or planned administration during the study period.\n\n          -  Pregnant or lactating female.\n\n          -  Female planning to become pregnant or planning to discontinue contraceptive\n             precautions."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "16 Years", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01847430", 
            "org_study_id": "116722", 
            "secondary_id": "2012-003950-10"
        }, 
        "intervention": {
            "arm_group_label": "HBV Group", 
            "description": "3 doses administered intramuscularly in deltoid region of non-dominant arm.", 
            "intervention_name": "Engerix\u2122-B Kinder", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": "Hepatitis B Antibodies"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Healthy", 
            "Hepatitis B", 
            "Adolescents", 
            "Engerix\u2122-B Kinder"
        ], 
        "lastchanged_date": "January 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kehl", 
                        "country": "Germany", 
                        "state": "Baden-Wuerttemberg", 
                        "zip": "77694"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tuttlingen", 
                        "country": "Germany", 
                        "state": "Baden-Wuerttemberg", 
                        "zip": "78532"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bindlach", 
                        "country": "Germany", 
                        "state": "Bayern", 
                        "zip": "95463"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kirchheim", 
                        "country": "Germany", 
                        "state": "Bayern", 
                        "zip": "85551"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Goch", 
                        "country": "Germany", 
                        "state": "Nordrhein-Westfalen", 
                        "zip": "47574"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankenthal", 
                        "country": "Germany", 
                        "state": "Rheinland-Pfalz", 
                        "zip": "67227"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "state": "Sachsen", 
                        "zip": "04178"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Flensburg", 
                        "country": "Germany", 
                        "state": "Schleswig-Holstein", 
                        "zip": "24937"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "13055"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Neumuenster", 
                        "country": "Germany", 
                        "zip": "24534"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Long-term Persistence of Hepatitis B Antibodies and Immune Response to a Challenge Dose of GSK Biologicals' HBV Vaccine, Engerix\u2122-B Kinder (SKF103860), in 15-16 Years Old Adolescents, Vaccinated in Infancy With Engerix\u2122-B Kinder", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Evaluation of anti-HBs immune status in terms of antibody concentrations", 
            "safety_issue": "No", 
            "time_frame": "One month after the challenge dose (Month 1)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01847430"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Evaluation of anti-HBs immune status in terms of antibody concentrations", 
                "safety_issue": "No", 
                "time_frame": "Before (Day 0) and one month after the challenge dose (Month 1)"
            }, 
            {
                "measure": "Occurrence of solicited local and general symptoms", 
                "safety_issue": "No", 
                "time_frame": "During the 4-day (Days 0-3) follow-up period after the challenge dose"
            }, 
            {
                "measure": "Occurrence of unsolicited adverse events", 
                "safety_issue": "No", 
                "time_frame": "During the 31-day (Days 0-30) follow-up period after the challenge dose"
            }, 
            {
                "measure": "Occurrence of serious adverse events (SAEs)", 
                "safety_issue": "No", 
                "time_frame": "After challenge dose, up to study end (Month 1)"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}